These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22461527)

  • 1. Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine.
    Moran EE; Burden R; Labrie JE; Wen Z; Wang XM; Zollinger WD; Zhang L; Pinto VB
    Clin Vaccine Immunol; 2012 May; 19(5):659-65. PubMed ID: 22461527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
    Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
    Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.
    Pinto VB; Moran EE; Cruz F; Wang XM; Fridman A; Zollinger WD; Przysiecki CT; Burden R
    Vaccine; 2011 Oct; 29(44):7752-8. PubMed ID: 21827811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.
    Koeberling O; Delany I; Granoff DM
    Clin Vaccine Immunol; 2011 May; 18(5):736-42. PubMed ID: 21367981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
    Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
    Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.
    Pinto VB; Burden R; Wagner A; Moran EE; Lee CH
    PLoS One; 2013; 8(11):e79304. PubMed ID: 24244473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation and Immunogenicity of
    Manoharan S; Farman TA; Piliou S; Mastroeni P
    Front Immunol; 2024; 15():1473064. PubMed ID: 39380985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
    Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
    Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease.
    Harris SL; Zhu D; Murphy E; McNeil LK; Wang X; Mayer LW; Harrison LH; Jansen KU; Anderson AS
    Hum Vaccin; 2011; 7 Suppl(Suppl):68-74. PubMed ID: 21245657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
    Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
    Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine.
    Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X
    mBio; 2019 Sep; 10(5):. PubMed ID: 31506309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
    Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
    Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.
    Pajon R; Fergus AM; Koeberling O; Caugant DA; Granoff DM
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1302. PubMed ID: 21909444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
    Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
    Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.
    Findlow J; Borrow R; Snape MD; Dawson T; Holland A; John TM; Evans A; Telford KL; Ypma E; Toneatto D; Oster P; Miller E; Pollard AJ
    Clin Infect Dis; 2010 Nov; 51(10):1127-37. PubMed ID: 20954968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.
    Koeberling O; Giuntini S; Seubert A; Granoff DM
    Clin Vaccine Immunol; 2009 Feb; 16(2):156-62. PubMed ID: 19109451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
    Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
    Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.